These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 11902983

  • 1. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
    Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ.
    Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
    [Abstract] [Full Text] [Related]

  • 2. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC, Worldwide Bexarotene Study Group.
    Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
    [Abstract] [Full Text] [Related]

  • 3. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
    Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD, Worldwide Bexarotene Study Group.
    J Am Acad Dermatol; 2003 Nov; 49(5):801-15. PubMed ID: 14576658
    [Abstract] [Full Text] [Related]

  • 4. Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma.
    Liu HL, Kim YH.
    Arch Dermatol; 2002 Mar; 138(3):398-9. PubMed ID: 11902993
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term control of mycosis fungoides of the hands with topical bexarotene.
    Lain T, Talpur R, Duvic M.
    Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP, Levitan D, Fleischer AB.
    J Dermatolog Treat; 2009 Mar; 20(3):169-76. PubMed ID: 19016373
    [Abstract] [Full Text] [Related]

  • 11. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
    Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, Steckel S.
    Cancer; 2007 May 01; 109(9):1799-803. PubMed ID: 17366595
    [Abstract] [Full Text] [Related]

  • 12. Topical and oral bexarotene.
    Schadt CR.
    Dermatol Ther; 2013 May 01; 26(5):400-3. PubMed ID: 24099070
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials.
    Prince HM, McCormack C, Ryan G, Baker C, Rotstein H, Davison J, Yocum R.
    Australas J Dermatol; 2001 May 01; 42(2):91-7. PubMed ID: 11309029
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
    Lewis DJ, Huang S, Duvic M.
    Dermatol Ther; 2017 Sep 01; 30(5):. PubMed ID: 28748653
    [Abstract] [Full Text] [Related]

  • 19. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
    Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC, Bexarotene Worldwide Study Group.
    J Clin Oncol; 2001 May 01; 19(9):2456-71. PubMed ID: 11331325
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.